Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Submits Dapoxetine NDA For Premature Ejaculation

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.
Advertisement

Related Content

Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up
Intrinsa Advisory Cmte. Decision Should Not Affect Dapoxetine, PPD Says
Intrinsa Advisory Cmte. Decision Should Not Affect Dapoxetine, PPD Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS058478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel